Experimental cell therapy takes on tough blood cancers
NCT ID NCT04629729
First seen Jan 08, 2026 · Last updated May 21, 2026 · Updated 24 times
Summary
This early-phase trial tests a new treatment called FT819 for people with B-cell blood cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The treatment uses specially engineered immune cells to target and attack cancer cells. The main goals are to find a safe dose and check for side effects, while also seeing if the therapy can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Florida
Jacksonville, Florida, 32224, United States
-
Mayo Minnesota
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky, 40207, United States
-
Oregon Health & Sciences University
Portland, Oregon, 97239, United States
-
Scripps Green Hospital
La Jolla, California, 92037, United States
-
Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
UC Davis
Davis, California, 95817, United States
-
UCLA Ronald Reagan Medical Center
Los Angeles, California, 90095, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Florida
Gainesville, Florida, 32608, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin-Madison
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.